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The reservoir of HIV latently infected cells is the major obstacle for
eradication of HIV infection. The “shock-and-kill” strategy pro-
posed earlier aims to reduce the reservoir by activating cells out
of latency. While the intracellular HIV Tat gene circuit is known to
play important roles in controlling latency and its transactivation
in HIV-infected cells, the detailed control mechanisms are not well
understood. Here we study the mechanism of probabilistic control
of the latent and the transactivated cell phenotypes of HIV-
infected cells. We reconstructed the probability landscape, which
is the probability distribution of the Tat gene circuit states, by
directly computing the exact solution of the underlying chemical
master equation. Results show that the Tat circuit exhibits a clear
bimodal probability landscape (i.e., there are two distinct proba-
bility peaks, one associated with the latent cell phenotype and the
other with the transactivated cell phenotype). We explore poten-
tial modifications to reactions in the Tat gene circuit for more
effective transactivation of latent cells (i.e., the shock-and-kill
strategy). Our results suggest that enhancing Tat acetylation can
dramatically increase Tat and viral production, while increasing
the Tat–transactivation response binding affinity can transactivate
latent cells more rapidly than other manipulations. Our results
further explored the “block and lock” strategy toward a functional
cure for HIV. Overall, our study demonstrates a general approach
toward discovery of effective therapeutic strategies and drug-
gable targets by examining control mechanisms of cell phenotype
switching via exactly computed probability landscapes of reaction
networks.
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H IV infection is a global epidemic and currently over36 million people worldwide live with the virus (1). Present
antiretroviral therapies (ARTs) can effectively suppress HIV
viral replication by disrupting the viral life cycle at multiple
stages. However, they do not eradicate HIV infection. The major
barrier for complete eradication of HIV from the host is the
reservoir of latently infected CD4+ T cells. These cells are not
recognized by the immune system and their persistence is not
affected by ART. Latency transactivation is the process of
transition from the latent state, in which HIV gene transcription
is largely inactive, to the transactivated state with active HIV
gene transcription and viral replication. Latent cells can sto-
chastically transactivate to actively produce new virions, resulting
in viral rebound once ART is interrupted. To eradicate HIV
from the host, the latent reservoir must be eliminated.
The HIV latent reservoir is extremely stable, with an estimated
half-life of ∼44 mo (2–4). Given the large number (>106) of
latently infected cells within a host, it would take ∼70 y for the
loss of all latent cells, even if no new latently infected cells were
generated due to the administration of ART (2, 3). The “shock-
and-kill” strategy was proposed to eradicate the latent reservoir
by activating latently infected cells using latency reversing agents
(LRAs) (5–8), so they can be eliminated either by the immune
system or by viral cytopathic cell death. However, recent clinical
trials and experiments with histone deacetylase inhibitor
(HDACi)-based LRAs did not show effective reductions in the
latent reservoir (5–8). Novel LRAs are needed for more effective
activation and killing of latently infected cells.
To eliminate the HIV latent reservoir, it is important to un-
derstand the mechanisms that control the stability of HIV la-
tency, so strategies can be designed to destabilize latency and
thereby help eliminate the latent reservoir. The latency of HIV-
infected cells and their transactivation are stochastically con-
trolled by the HIV Tat gene circuit (9–11). Tat, the trans-
activator of transcription, is a critical regulatory protein encoded
in the HIV genome and is under the control of a single HIV
promoter, the LTR. The Tat gene circuit was experimentally
found to be sufficient to generate bimodal phenotypes of latency
and transactivation independent of the CD4+ T cell resting state
(9, 12). While circuits of genetic switches with bimodal control
have been extensively studied in systems such as Escherichia coli
(13) and phage lambda (14–17), the HIV Tat gene circuit is
different. The Tat circuit consists of a single positive feedback
loop and does not contain any double-negative feedbacks (9, 12).
In addition, it exhibits no cooperativity (9, 12). Mathematical
models have shown that simple positive feedback loops without
cooperativity cannot maintain a stable off-state and therefore do
not have deterministic bistability (18–20). However, it is well
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known that bistability can be induced by stochasticity in small-
volume systems, such as cells, (21–23) or by stochastic gene
regulatory networks (9, 12, 20, 24–27), contrary to what is pre-
dicted by corresponding deterministic models (e.g., based on
mass action). How the bimodality of latency and transactivation
is controlled through the Tat gene circuit and which reactions are
the controlling ones remain unanswered questions.
Cell phenotypes are controlled by intracellular reaction net-
works that are intrinsically stochastic. Understanding the regu-
latory mechanism of cell phenotypes relies on effective models
and efficient algorithms to predict the correct cell behavior from
the underlying reaction networks. Accurate characterization of
the probability landscape of intracellular reaction networks
provides a powerful approach to study the probabilistic control
and switching of cell phenotypes, and significant progress has
been made in this field (14, 28–33). Here we systematically
investigate the stochastic control of HIV latency and trans-
activation by characterizing the full probability landscape of the
Tat circuit under different conditions. This is achieved by directly
solving the underlying chemical master equation (CME) using
the accurate CME (ACME) method (14, 31–33). By taking ad-
vantage of the strong coupling among reactions, the ACME
method can dramatically reduce the size of the required state
space and therefore allows exact computation of the probability
landscapes with mathematically derived error bounds (32, 33) for
many stochastic networks that were otherwise infeasible (14, 31–
33). Importantly, the rate of HIV phenotype switching between
latency and transactivation can be accurately calculated using the
ACME method (32, 33).
In this study, we first characterize the full probability land-
scape of the wild-type HIV Tat circuit at steady state and then
compute the landscapes with different model parameters to in-
vestigate the stability and regulatory mechanisms that control the
latency phenotype. We further identify potential therapeutic
targets based on probability landscapes and compute phenotype
switching rates for effectively reversing the latent state of HIV-
infected cells and thereby facilitating depletion of the HIV latent
reservoir.
Materials and Methods
The reaction scheme of the HIV Tat gene circuit used in this study is shown in
Fig. 1A (9, 11, 12, 34–36). The detailed reactions are listed in SI Appendix,
Table S1. Among proteins encoded by the HIV genome, the Tat protein is
essential for HIV production (11). In the absence of Tat, the basal tran-
scription of HIV genes, including tat, can initiate from the LTR region but
cannot elongate efficiently. Upon initiation, the RNA polymerase II tran-
scription complex pauses at the promoter proximal location (11, 37–40).
Further elongation only occurs at an extremely low basal transcription rate
(kb0). The premature HIV mRNA fragment generated from the initiated
transcription forms the HIV transactivation response (TAR) element, which is
a highly stable RNA stem–loop structure (41). When Tat is available, it binds
the TAR element in the paused transcription complex at binding rate kb to
recruit the positive transcription elongation factor (P-TEFb), an essential host
transcription regulator in eukaryotes, to the paused transcription complex to
form the Tat–TAR–P-TEFb (TTP) complex. The Tat protein in the TTP complex
can be acetylated at lysines 25, 50, and 51 (42, 43) at rate ka and represented
as acTTP (SI Appendix, Table S1). After Tat acetylation, the P-TEFb complex is
released to hyperphosphorylate the C-terminal domain of the RNA poly-
merase II (44), so that the paused transcription complex can transition to
productive elongation and a mature HIV mRNA can be synthesized at a
transactivated rate kf . Tat is then released from the complex after elonga-
tion and is available for another cycle of transactivation. By recruiting P-TEFb
to speed up transcription, the HIV Tat gene circuit forms a Tat-dependent
positive feedback loop in the transactivation of HIV (Fig. 1B). In this circuit,
Tat can be produced from two different modes: either from slow Tat-
independent basal production or from rapid Tat-dependent transactivated
production. These two modes have substantially different production rates
of Tat, and implicitly of other HIV proteins. Values of parameters for the Tat
circuit (SI Appendix, Table S1) were obtained from the literature. For those
parameters with no accurate experimental measurements, we used values
from previous modeling studies (9, 12, 24, 36) and complemented them with
detailed exploration of the sensitivity of our results to the choice of these
parameter values. Additional justifications for parameter choices and details
of the ACME method can be found in SI Appendix.
Results
HIV Tat Circuit Exhibits Stochastic Bimodality of Latency and
Activation. We computed the steady-state probability landscape
of the HIV Tat circuit and projected it onto the 2D space of Tat
mRNA and Tat protein (Fig. 2A, top view and Fig. 2B, side
view). Our results show that the Tat circuit exhibits bimodality
(i.e., has two distinct probability peaks) (Fig. 2). The first peak,
which corresponds to latency, is located at zero copies of both
Tat mRNA and Tat protein with a maximum probability of 0.98
(Fig. 2). The second peak located at 3 copies of mRNA and 93
copies of Tat protein, with a small peak probability of 3.2× 10−5
(Fig. 2), corresponds to the transactivated cell phenotype. We
define the stochastic separatrix state as the state with the lowest
probability between the two probability peaks. For the wild-type
Tat circuit, the separatrix state has 1 copy of Tat mRNA and 34
copies of Tat protein (Fig. 2A, yellow square). For easier com-
parison, we further project the probability landscape onto the 1D
space of Tat protein copy number (SI Appendix, Fig. S1A), in
which the separatrix state is at 16 copies of Tat protein (SI Ap-
pendix, Fig. S1A, dashed red line). The latency probability peak is
high, sharp, and narrow (Fig. 2B and SI Appendix, Fig. S1A),
which explains the high stability of HIV latency. That is, once a
cell is in latency, it is difficult to become spontaneously reac-
tivated. In contrast, the peak of transactivation is very broad and
shallow (Fig. 2A and SI Appendix, Fig. S1A); the variance-to-
mean ratio for Tat copy number in transactivated cells with
greater than 16 copies of Tat protein is calculated to be 29.
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Fig. 1. The HIV Tat circuit. (A) Detailed molecular interactions in the Tat
gene circuit (SI Appendix, Table S1). (B) The backbone positive feedback
logic in the Tat circuit.
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Fig. 2. Bimodal steady-state probability landscape of HIV Tat circuit. (A) Top
view of the 2D steady-state landscape. The contour lines show the proba-
bility in log scale. The yellow triangle indicates the location of probability
peak of latency, the yellow circle indicates the location of the probability
peak of activation, and the yellow square indicates the stochastic separatrix
state. (B) Perspective view of the 2D steady-state landscape. The yellow tri-
angle in the bottom left corner of A corresponds the high peak of latency
shown in red in B.
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Positive Feedback Is Essential for Transactivation. To study the
contribution of the positive feedback loop in the control of HIV
latency and transactivation, we first disrupted the positive feedback
by blocking Tat–TAR binding, that is, by setting kb = 0 in the model,
and found that the probability peak of transactivation disappears (SI
Appendix, Figs. S1B and S2A). Although a small probability shoul-
der remains at around 20 copies of Tat protein, which suggests that
it is still possible to transactivate from the latent state, however it
may not be able to efficiently sustain transactivation events, where a
large copy number of Tat protein may be required (SI Appendix,
Figs. S1B and S2A). This unimodal probability landscape suggests
that upon inhibition of Tat–TAR binding, latency is the only stable
cell phenotype (SI Appendix, Figs. S1B and S2A). The effect of
disrupting the positive feedback through blocking Tat acetylation
(by setting ka = 0) yields a probability landscape that exhibits the
same qualitative behavior (SI Appendix, Fig. S2B).
To further characterize the role of the positive feedback loop in
the Tat circuit, we compare the behavior of the wild-type and the
two differently perturbed circuits by examining their rates of
transactivation from latency, rates of returning to latency from the
activated state and their 95 percentile amplitudes of Tat copy
number in activated cells. Detailed procedures for obtaining the
phenotype switching rates are described in SI Appendix. While the
Tat circuit is modeled in single cells, its steady-state probability
landscape is the distribution of all possible cell phenotypes in a
population of cells carrying the identical Tat circuit. Therefore, the
computed rates correspond to the transition rates between the la-
tent reservoir and the transactivated cell population.
The computed transactivation rate with the wild-type Tat
circuit is 4.5× 10−4   d−1 (SI Appendix, Table S2). For a population
of latently infected cells with identical parameters, this corre-
sponds to a half-life of 51 mo (SI Appendix, Table S2). The rate
corresponds to the occurrence of 450 independent Tat circuit
transactivation events per day from a latent reservoir of size 106.
The rate of returning to latency is computed to be 0.065 per day
(SI Appendix, Table S2), which is 1,400-fold larger than the la-
tency transactivation rate and shows the low stability of the
transactivated state. The rates are shown in SI Appendix, Table
S1. The number of Tat circuit transactivation events per day not
only depends on the transactivation rate but also on the size of
the latent reservoir (SI Appendix, Table S1).
Compared with the wild-type Tat circuit, a Tat circuit without
positive feedback would have much smaller latency trans-
activation rates (3.4 × 105 d−1, roughly 10-fold smaller than the
wild-type Tat circuit, SI Appendix, Table S2) with extremely long
latent reservoir half-lives (SI Appendix, Table S2). The circuits
also have a much higher rate of returning to latency and much
smaller Tat copy numbers in transactivated cells (SI Appendix,
Table S2). Overall, these results show that the positive feedback
is essential in transactivating the Tat circuit in latently infected
cells. Without positive feedback, the Tat circuit in latently in-
fected cells cannot be effectively transactivated.
Tat Acetylation and Tat–TAR Binding Control Bimodal Phenotype.
Depending on parameters, the Tat circuit can exhibit three differ-
ent types of probability landscapes at steady state: (i) unimodality at
latency, which has a single probability peak at zero copies of Tat
mRNA and protein, (ii) unimodality at transactivation, which has a
single probability peak at nonzero copies of Tat mRNA and protein,
and (iii) stochastic bimodality, which has two probability peaks, one
at zero Tat copy number and the other at high Tat copy number. We
study the effect of changing the rates of different reactions in the Tat
circuit that may be potential drug targets to disrupt the bimodality
and induce transactivation. We perturb the basal transcription rate
(kb0), the nuclear import and export rates (ke and ki), the Tat–TAR
binding and unbinding rates (kb and ku), and the Tat acetylation and
deacetylation rates (ka and kd). We examine the effect of pertur-
bations of these reactions on the steady-state probability landscape.
Since perturbing the basal transcription rate does not eliminate the
transactivation peak (SI Appendix, Fig. S3) and perturbing Tat
mRNA export and Tat protein import does not eliminate the latency
peak (SI Appendix, Figs. S4 and S5), we focus on the perturbations of
Tat acetylation/deacetylation rates and Tat–TAR binding/unbinding
rates. The results are summarized in SI Appendix, Table S3.
Perturbations of Tat acetylation/deacetylation rates and Tat–
TAR binding/unbinding rates dramatically disrupt the bimodal
probability landscape (SI Appendix, Figs. S6 and S7). When the
Tat acetylation rate, ka, is large, or the deacetylation rate, kd, is
small, the Tat circuit exhibits only one probability peak at the
transactivation state (red region in Fig. 3A and SI Appendix, Fig.
S6). When the acetylation rate is small and the deacetylation is
large, the Tat circuit exhibits only one probability peak at latency
(blue region in Fig. 3A and SI Appendix, Fig. S6). Interestingly,
between the regions of unimodal latency and unimodal trans-
activation there is a narrow region in which the Tat circuit ex-
hibits bimodality (yellow region in Fig. 3A) with the presence of
probability peaks corresponding to latency and transactivation
(SI Appendix, Fig. S6). That is, both phenotypes are possible
under conditions defined by this narrow region. Perturbing the
Tat–TAR binding and unbinding rates have similar effects (SI
Appendix, Fig. S7), but with a wider region of bimodality (Fig.
3B). In addition, perturbations in reactions can also change the
shape of the probability landscapes. Increasing the Tat acetyla-
tion rate can dramatically shift the peak of transactivation to a
much higher Tat copy number (SI Appendix, Fig. S6), while
perturbing other parameters has little effect on the mode of the
transactivation peak (SI Appendix, Figs. S3, S4, and S7).
Tat Acetylation and Tat–TAR Binding Control Intracellular Tat Copy
Number and Transactivation Rate.We examined how Tat acetylation/
deacetylation and Tat–TAR binding/unbinding affect the pro-
duction of Tat protein during latency transactivation. We first
identified the peak of transactivation, which is separated from the
peak of latency in the steady-state probability landscape by the
stochastic separatrix (e.g., red dashed line in SI Appendix, Fig. S1A).
The mean and variance of the Tat copy number in the trans-
activation peak were calculated at different model conditions. Re-
sults show that altering the Tat acetylation and deacetylation rates
will result in a significantly larger mean copy number of Tat protein
than altering the Tat–TAR binding/unbinding rates (Fig. 4 and SI
Appendix, Table S4), while both are larger than the wild-type Tat
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Fig. 3. Phase diagrams of cell phenotypes when perturbing the Tat acety-
lation/deacetylation rates and the Tat–TAR binding/unbinding rates. Distri-
bution of unimodal and bimodal cell phenotypes in the Tat acetylation and
deacetylation parameter space (A) and in the Tat–TAR binding and un-
binding parameter space (B). Blue region: unimodality at latency. Red re-
gion: unimodality at transactivation. Yellow region: stochastic bimodality
with both latent and transactivated cell phenotypes possible.
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circuit. The variance of the Tat copy number at the transactivation
peak is also altered.
The rate of latency transactivation and the rate of returning to
latency can be significantly impacted by the rates of Tat acetylation/
deacetylation and Tat–TAR binding/unbinding. In comparison, de-
creasing the Tat deacetylation rate is less effective in increasing the
latency transactivation rate than increasing the Tat–TAR binding
rate. A 100-fold decrease in the Tat deacetylation rate only increases
latency transactivation by 1.4-fold and reduces the half-life of the
latent reservoir by 31% (SI Appendix, Fig. S8 and Table S4), whereas
a 100-fold increase of the Tat–TAR binding rate can increase the
rate of latency transactivation by about 1.8-fold and it reduces the
half-life of the latent reservoir by 45% (SI Appendix, Fig. S8 and
Table S4). Additionally, the rate of returning to latency is dramat-
ically reduced by all four reaction perturbations, which makes la-
tency transactivation almost irreversible (SI Appendix, Table S4).
Discussion and Conclusions
Current ART can effectively suppress within-host HIV replication,
but it does not eradicate HIV infection. The long-term persistence
of the HIV latent reservoir forms the major barrier for the complete
eradication of HIV. Latency transactivation is the process of tran-
sition from the latent state, in which HIV gene transcription is
largely inactive, to the transactivated state with active HIV gene
transcription and viral replication. In the transactivated state la-
tently infected cells can be killed by viral cytopathic effects or be
recognized and killed by immune system effector cells. While the
shock-and-kill strategy has been proposed to reduce the size of the
latent reservoir, a shock using HDACi-based LRAs has so far failed
to reduce the latent reservoir (5, 7, 8, 45, 46).
The intracellular Tat circuit is known to play an important role
in controlling latency and its transactivation in HIV-infected
cells (9–12, 47). However, it has not been targeted for latency
reversal. In this study, we characterized the maintenance and the
transition kinetics between the cellular phenotypes of latency
and transactivation through computational modeling of the HIV
Tat circuit. Using this model, we further identified potential
targets in the Tat circuit for therapeutic interventions toward
latency reversal. To simplify the model, we only consider spon-
taneous transactivation of latently infected cells and not trans-
activation due to antigen stimulation. We also assume latently
infected cells have quiescent HIV transcription and thus do not
express HIV epitopes that can lead to their recognition and
death by immune-mediated mechanisms. As the transitions from
latency to the activated state are rare events, for which simula-
tion methods such as the Gillespie algorithm (48) are not ef-
fective, quantifying the probabilistic behavior of the Tat circuit is
technically challenging. In this study, we directly computed the
probability landscapes of the Tat circuit and the rate of latency
transactivation using the ACME method (14, 31–33).
Our results revealed the probabilistic bimodal control mecha-
nism of HIV latency and transactivation. Our results showed that
the steady-state probability landscape of HIV-infected cells con-
trolled by the Tat circuit can simultaneously exhibit two distinct
probability peaks corresponding to latent and transactivated cell
phenotypes. The latency peak is high and narrow, indicating a
stable latent state. The transactivation peak is low and broad, in-
dicating a less-stable state with a highly fluctuating copy number of
Tat protein in transactivated cells. This high level of Tat fluctua-
tion likely contributes to the observed large variability in the
amount of HIV produced from activated cells (49). The stability of
the latent state in the wild-type HIV Tat circuit is maintained by
both the slow transition from the latent state to the transactivated
state and the faster transition from the transactivated state back to
the latent state (SI Appendix, Table S2).
Based on the computed latency transactivation rate, the
computed 51-mo half-life of latent reservoir with identical wild-
type Tat circuit parameters is close to the current estimate of
∼44 mo based on clinical data (3, 4). Hill et al. (50) estimated the
frequency of successful transactivation from latent reservoir that
lead to viral rebound after cessation of ART to be approximately
four per day, whereas Pinkevych et al. (51) estimated the fre-
quency to be one in every 5–8 d. Assuming 106 latently infected
cells in the latent reservoir, that is, a total of 1011 CD4+ T cells in
a HIV-1–infected individual with 10 in a million being latently
infected, our model predicts 450 independent Tat circuit trans-
activations per day. The size of the latent reservoir can vary by
orders of magnitude among patients and the frequency of pre-
dicted transactivation events will then also vary (52). Following
Tat circuit transactivation many other events need to occur be-
fore viremia would be observed. An activated cell might die before
producing any virus or the virus released may be cleared before
infecting another cell. Our model does not predict the frequency of
successful transactivation events as in Hill et al. (50) and Pinkevych
et al. (51); rather, it only predicts the number of events in which the
Tat copy number exceeds a predefined threshold needed for
transactivation. Therefore, the predicted Tat circuit transactivation
frequency of 450 d−1 is necessarily greater than the frequency of
successful transactivation that eventually led to viral rebound.
The transactivation rate was computed based on the trans-
activation events from the wild-type Tat circuit without taking
into consideration other factors, such as necessary host factors
(53, 54), the organization and structure of chromatin (55–57),
epigenetics and DNA and chromatin modification (56), and the
metabolic state of the host cell (58). These factors are required
but may not be available in latently infected resting memory CD4+
T cells for successful transactivation and viral replication. Thus,
the actual rate of transactivation may be lower and the reservoir
half-life longer than we estimated above. Moreover, antigen-
induced activation of latently infected CD4+ T cells would be
expected to shorten the half-life. Since these factors may affect the
half-life of latent reservoir, a computation of half-life based solely
on the Tat circuit may be inaccurate but is a necessary first step in
gaining insight into the required processes and their kinetics.
We identified potential targets for therapeutic interventions
toward reversing latency. While transactivation events occur in a
probabilistic fashion, exact quantification of the probability
landscape of the Tat circuit enables prediction of the effects of
possible circuit modifications on the overall expected behavior of
the cell. We set out to identify specific reactions in the circuit
whose alteration can tilt the probability landscape in such a way
that the HIV latent reservoir can be depleted more effectively.
Our results showed that perturbing Tat acetylation/deacetylation
and the Tat–TAR binding/unbinding can effectively eliminate
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latency or suppress the transactivation. To compare the effectiveness
of manipulating these different reactions, we compared the mean
intracellular Tat copy number in transactivated cells and the rate of
latency transactivation at the same levels of change in the re-
action rate. Our results suggest that both manipulations of Tat–
TAR binding/unbinding and Tat acetylation/deacetylation can
induce higher intracellular copy number of Tat protein than the
wild-type Tat circuit in transactivated cells. However, the in-
tracellular Tat copy number when manipulating Tat acetylation/
deacetylation can be much higher than when manipulating Tat–
TAR binding/unbinding. Due to the role of Tat in transactivating
HIV replication, higher intracellular Tat may lead to higher pro-
duction of HIV proteins, which can help immune cells to target and
destroy infected cells. However, high intracellular Tat may also
induce higher production of HIV virions, which can further lead to
reseeding of the HIV latent reservoir and compromise the effect of
reservoir depletion, unless potent ART is given that can suppress
nearly all de novo viral infection (59). While the intracellular Tat
copy number is higher with Tat acetylation/deacetylation manipu-
lations than with Tat–TAR binding/unbinding manipulations, we
found surprisingly that the latency transactivation rate with ma-
nipulations of Tat–TAR binding/unbinding is faster than with ma-
nipulation of Tat acetylation/deacetylation. However, the lower
intracellular Tat protein level in Tat–TAR binding/unbinding ma-
nipulation may result in weaker immune response and cell killing
rate in a shock-and-kill strategy. Therapies based on a combination
of increase in Tat acetylation and Tat–TAR binding rates are likely
to be more effective.
HDACis, such as vorinostat (60, 61), panobinostat (6), and
romidepsin (62), have been tried as LRAs, though unsuccessful
clinically (5, 7, 8, 62), due to their effects on opening chromatin
structure and exposing HIV genes for active transcription. Since
deacetylation of Tat is a critical step in the Tat circuit, deacetylase
inhibitors can potentially affect Tat deacetylation (43, 63) and
therefore directly interfere with Tat-mediated transactivation.
Overall, to activate latently infected cells for shock and kill, our
model suggests that if agents can be found to effectively and spe-
cifically increase Tat acetylation rate and Tat–TAR binding rate to
the same level as HDAC inhibitors do for the deacetylation rate
they might be more effective LRAs than HDACis.
In addition to shock and kill, our results can also help evaluate
the strategy toward a functional cure. The ability of long-term
viral suppression after termination of ART provides an impor-
tant treatment strategy alternative to eradication. Our model
showed that transactivation of the Tat circuit can be strongly
suppressed by disrupting the Tat positive feedback loop through
inhibition of Tat acetylation or Tat–TAR binding to the degree
that the activated cells are forced back into a “deep latent” state
with a diminished transactivation rate. According to our model,
the positive feedback loop is essential for the bimodal phenotype
and effective transactivation. Several recently discovered small
molecules might be able to block the positive feedback. For ex-
ample, didehydro-cortistatin A (dCA) can strongly inhibit Tat–
TAR binding (64–66). Neomycin can also inhibit Tat–TAR
binding and increase the unbinding rate (67). A synthetic oli-
gonucleotide complementary to the HIV-1 TAR RNA apical
stem–loop was also found to strongly inhibit Tat–TAR interaction
(68). Our results showed that although complete removal of the
positive feedback eliminates the distinct probability peak of
transactivation from the probability landscape, the residual tail
probability at large Tat copy number (SI Appendix, Fig. S1) may
still support transactivation with low probability. Based on the
probability landscapes, the model predicted the removal of posi-
tive feedback reduces the latent cell transactivation rate by
roughly 10-fold. For a host with a large (∼106) latent reservoir, a
10-fold reduction may not effectively suppress activation from
latency. Hence, our model suggests one ought to be cautious
about the effectiveness of “block and lock.”
Our study on the Tat circuit behavior in individual cells pro-
vides important insights into understanding the intracellular
probabilistic control of HIV latency. However, there are many
factors beyond the Tat circuit that are not currently incorporated
in this model. First, since we do not model intercellular inter-
actions, such as new infections and viral replication; the current
model only explains the behavior of an HIV latent reservoir with
identical Tat circuit parameters in an ART-suppressed patient.
Second, the toggling of the ON and OFF state of HIV promoter
may also play a role in controlling the latency–transactivation
bimodality (12, 24). Without explicitly modeling the ON/OFF
toggling of HIV promoter, the interpretations of our model are
bound to assumptions that either the HIV promoter is constantly
turned on, or the slow promoter ON/OFF toggling is implicitly
encoded in the slow basal transcription rate. Third, our model
does not incorporate the constraining factors in resting memory
CD4+ T cells for maintaining the state of latency, which might be
important since a large fraction of latently infected cells are
resting memory CD4+ T cells (2, 69). Finally, the immune re-
sponse against infected cells forms an additional layer of com-
plexity for strategies such as shock and kill (70–72). These
mechanisms all likely have important roles in the control of viral
latency and transactivation. Incorporating these mechanisms in
future modeling studies will lead to improved understanding of
HIV latency and transactivation control.
Overall, our results showed that by studying the detailed in-
tracellular transcriptional control of HIV latency and trans-
activation one can discover more effective therapeutic targets
from the underlying reaction network for HIV latency reversal.
This approach can also be used to explore alternative strategies
for an HIV cure, such as a functional cure based on the block-
and-lock strategy (66) that attempts to enforce a state of “deep
latency.” The ACME method provides a powerful approach for
accurately studying the probabilistic behavior of cell phenotypes
controlled by the underlying stochastic gene regulatory networks.
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